In this exploratory analysis of the phase II HORIZON trial of melflufen plus dexamethasone in triple-class refractory multiple myeloma, which observation was reported?
Responses to melflufen appeared markedly better in patients previously treated with isatuximab than in those previously treated with daratumumab
Responses to melflufen were similar regardless of which anti-CD38 antibody patients had previously received
Patients previously treated with isatuximab had significantly more extramedullary disease at relapse than those treated with daratumumab